These tools may be particularly valuable for preoperative tumor characterization, early relapse detection, or treatment response monitoring, especially in tau-enriched LGGs, where molecularly targeted approaches could offer a more personalized and less invasive alternative to conventional diagnostic and therapeutic strategies. This evidence concerns the gene MAPT and neoplasm.